Abstract:Arteriosclerosis and its complications, such as heart attack and stroke, are the major causes of death in developed countries. It was believed that age, hyperlipidemia, hypertension, diabetes and smoking are common risk factors for cardiovascular disease. In addition, overwhelming clinical and epidemiological studies have identified homocysteine (Hcy) as a significant and independent risk factor for cardiovascular disease. In healthy individuals, plasma Hcy is between 5 and 10 micromol/L. One cause of severe hypehomocys- teinemia (HHcy) is the deficiency of cystathionine beta-synthase (CBS), which converts Hcy to cystathionine. CBS homozygous deficiency results in severe HHcy with Hcy levels up to 100 to 500 micromol/L. Patients with severe HHcy usually present with neurological abnormalities, premature arteriosclerosis. It has been reported that lowering plasma Hcy improved endothelial dysfunction and reduced incidence of major adverse events after percutaneous coronary intervention. The mechanisms by which Hcy induces atherosclerosis are largely unknown. Several biological mechanisms have been proposed to explain cardiovascular pathological changes associated with HHcy. These include: (1) endothelial cell damage and impaired endothelial function; (2) dysregulation of cholesterol and triglyceride biosynthesis; (3) stimulation of vascular smooth muscle cell proliferation; (4) thrombosis activation and (5) activation of monocytes. Four major biochemical mechanisms have been proposed to explain the vascular pathology of Hcy. These include: (1) autooxidation through the production of reactive oxygen species; (2) hypomethylation by forming SAH, a potent inhibitor of biological transmethylations; (3) nitrosylation by binding to nitric oxide or (4) protein homocysteinylation by incorporating into protein. In summary, our studies, as well as data from other laboratories support the concept that Hcy is causally linked to atherosclerosis, and is not merely associated with the disease. Although folic acid, vitamin B12 and B6 can lower plasma Hcy levels, the long-term effects on cardiovascular disease risk are still unknown and judgments about therapeutic benefits await the findings of ongoing clinical trials.

Hyperhomocysteinemia and Kidney Diseases

Association of hyperhomocysteinemia and chronic kidney disease in the general population: a systematic review and meta-analysis

Clinical Significance of Plasma Homocysteine in the Coronary Atherosclerosis Patients

The Kidney and Homocysteine Metabolism

Homocysteine:the common factor of heart and kidney injury

Homocysteine and Hyperhomocysteinaemia

Homocysteine, hyperhomocysteinemia, and H-type hypertension

Cardiovascular pathogenesis in hyperhomocysteinemia

Hyperhomocysteinemia Predicts Renal Function Decline: a Prospective Study in Hypertensive Adults

A review of homocysteine and heart failure

Homocysteine and heart failure: an overview.

Hyperhomocysteinemia Accelerates Acute Kidney Injury to Chronic Kidney Disease Progression by Downregulating Heme Oxygenase-1 Expression

Prevalence of Hyperhomocysteinemia (hhcy) and Its Major Determinants among Hypertensive Patients over 35 Years of Age.

Hyperhomocysteinemia and Hyperlipidemia in Coronary Heart Disease.

Relationship Between Hyperhomocysteinemia and Chronic Kidney Disease in Children

Hyperhomocysteinemia and atherosclerosis

Hyperhomocysteinemia and Vascular Injury: The Advance of Mechanisms and Drug Targets

[Hyperhomocysteinemia in patients with cardiovascular disease]

Mechanism of homocysteine-mediated endothelial injury and its consequences for atherosclerosis

Notable Epigenetic Role of Hyperhomocysteinemia in Atherogenesis.

Hyperuricemia and Kidney Diseases